Country Guide: Filing a Patent in Brazil

Brazil is the largest economy in Latin America, the seventh most populous country on earth, and home to one of the most challenging — and most misunderstood — patent systems in the world. For inventors in pharmaceuticals, agriculture, biotechnology, oil and gas, consumer goods, and information technology, Brazil represents a commercially significant market that is very difficult to protect in and very difficult to ignore.

Brazil's patent system has been shaped by a deliberate policy tension between IP protection and public health, domestic manufacturing, and economic development. Understanding that tension — not just the procedural rules — is essential to understanding why Brazilian prosecution works the way it does, and what strategies actually produce commercially useful patents.

The Hard Truth About Brazilian Patents

Brazil's INPI (Instituto Nacional da Propriedade Industrial) has one of the longest patent examination backlogs of any major patent office in the world. In the mid-2010s, average time from filing to first examination exceeded 10 years. A decade of reform efforts has reduced this — the current average for non-priority applications is approximately 7–9 years, with pharmaceutical applications sometimes faster due to a separate priority examination track. Even after examination begins, prosecution can take several more years.

This means a Brazilian patent application filed today in a standard technology area may not be granted until the mid-2030s. By that point, the patent will have 5–10 years of remaining term — and the commercial landscape will have changed substantially.

The practical consequence: Brazilian patents are primarily valuable for long-lifecycle technologies — pharmaceuticals, agricultural chemicals, industrial equipment, and material sciences — where a patent granted in 10 years still has commercial relevance. For fast-moving technology sectors, Brazilian patents often grant too late to provide meaningful competitive protection.

The second hard truth: Brazil has one of the most active environments globally for patent opposition and public interest challenges to pharmaceutical patents. NGOs, generic manufacturers, and the Brazilian government have systematically used administrative and judicial mechanisms to challenge foreign pharmaceutical patents on novelty, inventive step, and Section 229-C of the IP Law (which historically required ANVISA approval before patent grant). This environment reflects Brazil's genuine and ongoing commitment to access to medicines — inventors in pharmaceuticals must plan for opposition as a near-certainty, not a remote risk.

INPI: Overview

The Instituto Nacional da Propriedade Industrial, headquartered in Rio de Janeiro, administers patents, trademarks, industrial designs, geographical indications, and technology transfer registrations in Brazil. INPI is under the Ministry of Development, Industry, Commerce and Services (MDIC).

Annual filings: Approximately 26,000–30,000 patent applications per year, of which foreign applicants account for approximately 65–70%.

Types of Patent Protection

Invention Patent (Patente de Invenção — PI):

• Term: 20 years from filing date (minimum 10 years from grant if examination delay exceeds 10 years from filing — Brazil's "minimum term guarantee," a unique provision)
• Examination: Full substantive examination
• Covers: Products, processes, and improvements

Utility Model Patent (Modelo de Utilidade — MU):

• Term: 15 years from filing date (minimum 7 years from grant)
• Examination: Substantive examination (unlike German or Chinese utility models, Brazilian utility models are examined — but under a lower inventiveness standard)
• Covers: Objects of practical use, or parts thereof, susceptible to industrial application, which present a new form or arrangement, involving an inventive act, that results in a functional improvement in their use or manufacture
• Covers: Products only — not processes
• Note: Brazil's utility model is examined, making it more reliable than an unexamined registration, but slower than an unexamined German Gebrauchsmuster

The minimum term guarantee: Brazil's Law 9,279/1996 provides that patents must remain in force for at least 10 years after grant (15 years for utility models, 7 years). If INPI takes so long to grant the patent that the remaining term would be less than this minimum, the term is automatically extended to the minimum. This provision — unique to Brazil — was upheld by the Brazilian Supreme Court (STF) in 2021 in a landmark decision (ADI 5.529), though with limitations on its retroactive application. It means that despite the long examination timeline, patent holders are not simply cheated out of their effective term by bureaucratic delay.

What Is Patentable in Brazil

Brazil's IP Law (Law No. 9,279/1996) requires that patentable inventions be new, involve an inventive step, and be capable of industrial application — standard TRIPS requirements.

Key exclusions from patentability (Article 10):

• Discoveries, scientific theories, and mathematical methods
• Purely mental concepts, schemes, plans, or principles
• Artistic or literary works, or aesthetic creations
• Computer programs as such (though software-implemented inventions with a technical effect may be patentable)
• Presentation of information
• Rules of games
• Surgical or therapeutic methods for the treatment of the human or animal body, or diagnostic methods practised on the human or animal body

Article 18 — Absolute prohibitions:

• Inventions contrary to morals, good customs, public security, or public health
• Substances, matter, mixtures, elements, or products obtained by nuclear transformation
• Living beings in whole or in part, and biological material, even if isolated from their natural environment, including the genome or germplasm of any natural living being, and natural biological processes — this is the provision that has driven significant controversy over biotechnology and agricultural patents in Brazil

The pharmaceutical patent landscape: Brazil's Section 229-C (introduced in 2001, repealed in 2021) historically required ANVISA (Brazil's health regulatory agency) to provide a "prior consent" to INPI before a pharmaceutical patent could be granted. ANVISA used this mechanism to block patents it considered incompatible with public health policy — particularly for antiretroviral drugs and other essential medicines. The provision was repealed by Law 14,195/2021, removing ANVISA's formal prior consent role. However, ANVISA may still submit technical opinions during pharmaceutical patent examination, and the policy environment for pharmaceutical patents in Brazil remains particularly challenging.

Filing and Prosecution

Language

All INPI filings must be in Portuguese. A foreign-language specification can be filed initially, but a Portuguese translation must be provided within 60 days of filing (for direct applications) or at national phase entry (for PCT applications). Portuguese patent translation is a specialist function — technical accuracy in Portuguese patent drafting is essential, as translation errors can create specification support problems that are difficult to correct later.

Patent Agent Requirement

Foreign applicants must appoint a Brazilian intellectual property agent (Agente da Propriedade Industrial) registered with INPI. Brazilian IP law practice requires specific registration — not all lawyers are qualified to prosecute before INPI.

Direct National Filing

File directly at INPI through its e-INPI online portal. Applications require payment of filing fees in Brazilian reais.

Approximate government fees (2025):

• Invention patent filing: BRL 260–780 (depending on applicant size; significant reductions for microenterprises, small businesses, individual inventors, and universities)
• Examination request: BRL 780–2,340
• Annual maintenance: escalating from BRL 85/year (years 3–6) to BRL 1,170/year (years 14–20)

Brazil provides significant fee reductions for microenterprises, small businesses, individual inventors, universities, and public research institutions — one of the most accessible fee reduction structures of any major patent office.

PCT National Phase Entry

The most common route for foreign applicants. The deadline is 30 months from the international priority date.

Requirements: Portuguese translation; payment of national phase fees; appointment of a registered Brazilian IP agent.

Request for Examination

Substantive examination must be separately requested within 36 months of filing (or 36 months of the international filing date for PCT applications). Applications for which no examination request is filed within 36 months are irrevocably abandoned — unlike some other jurisdictions, there is no revival.

Priority Examination Tracks

Despite the standard 7–9 year backlog, INPI offers priority examination for:

Patents for Green Technology (PT-Verde): Applications relating to green technology — renewable energy, waste treatment, water purification, and emissions reduction — are eligible for priority examination, with first examination typically within 18–24 months.

Priority examination for elderly applicants and persons with disabilities

Examination for technology transfer agreements: Applications where a technology transfer agreement is being registered with INPI may receive priority treatment.

PPH (Patent Prosecution Highway): Brazil has PPH agreements with the EPO, JPO, KIPO, and several other offices. A PPH request, filed alongside the examination request when a corresponding application has been allowed elsewhere, can significantly accelerate examination.

Examination at INPI

How Examination Works

Brazilian examiners are technically qualified and apply examination standards broadly consistent with TRIPS. The examination report (exame de mérito) is the equivalent of an Office Action — it may raise novelty, inventive step, and formal objections.

Response period: 90 days from the examination report, extendable by 90 days on request.

The common rejection patterns in Brazil:

Lack of inventive step: The most frequent substantive rejection. Brazilian examiners apply an inventive step analysis that considers whether the invention would be obvious to a person skilled in the art, using a methodology broadly similar to the EPO's problem-solution approach. For pharmaceutical inventions, this analysis is particularly rigorous.

Breadth versus disclosure: Claims broader than what is specifically described and exemplified in the specification frequently receive written description and enablement rejections. Brazilian practice, like EPO practice, requires that claim scope be justified by the examples in the specification.

Article 10 exclusions: Particularly for software, business methods, and biotechnology inventions, INPI examiners apply the exclusions in Article 10 carefully. Software claims must demonstrate a technical effect beyond the mere execution of the program — abstract algorithmic claims receive strong rejection.

The ANVISA Legacy

Even after the formal repeal of the prior consent requirement, ANVISA may provide technical opinions to INPI during examination of pharmaceutical applications. These opinions are not binding but can influence examination. The Brazilian medical research community, NGOs, and public health advocates actively monitor pharmaceutical patent applications at INPI and submit third-party observations during examination — a mechanism provided by Brazilian IP law and actively used.

A Worked Example: The Long Game

A European pharmaceutical company filed a PCT application for a new antifungal compound. At PCT stage, the search report was positive — no close prior art identified. At Brazilian national phase entry (month 30), the company filed the application with a Portuguese translation and requested examination.

The first examination report arrived 8.5 years after the international filing date. It raised:

• A lack of inventive step rejection citing three references, including a Brazilian pharmaceutical research paper from a federal university that had not appeared in the PCT search
• A claim breadth rejection — the Markush group claim covering a family of compounds was considered broader than what the experimental examples demonstrated

The company's response required: engaging the Brazilian university paper in detail; submitting clinical data demonstrating efficacy across the Markush group; and narrowing the Markush claim to the specific analogues for which data was provided.

After one further exchange, the patent was granted — 11 years after the international filing date, with 9 years of remaining term (the minimum term guarantee adding 0 years, as the remaining term exceeded 10 years).

The lesson for pharmaceutical inventors: Budget for long prosecution timelines, budget for third-party observations, prepare clinical data packages that go beyond what may have been submitted elsewhere, and treat opposition as part of the standard prosecution plan rather than an exceptional event.

Enforcement in Brazil

The Federal Courts

Patent infringement cases in Brazil are heard by the federal courts. The most significant patent court activity is concentrated in São Paulo (where most technology companies and pharmaceutical businesses operate) and Rio de Janeiro (where INPI is based and where INPI administrative decisions are challenged).

Timeline: Brazilian patent litigation is slow. First-instance decisions in contested patent cases routinely take 5–10 years. Appeals to the Regional Federal Courts (TRFs) and the Superior Court of Justice (STJ) add further time.

Preliminary injunctions: Available in Brazil and regularly sought in patent infringement cases. Brazilian courts apply a four-part test: likelihood of success, irreparable harm, balance of interests, and public interest. For pharmaceutical patents, courts have been willing to grant preliminary injunctions but also willing to lift them when generic manufacturers demonstrate invalidity arguments.

Damages: Brazilian law provides for compensatory damages including lost profits and reasonable royalty. Brazilian courts have awarded increasingly significant damages in pharmaceutical and technology patent cases, though awards remain modest compared to US standards.

INPI Administrative Challenge

INPI provides administrative challenge mechanisms:

• Administrative nullity proceedings (Processo Administrativo de Nulidade — PAN): Any interested party can file an administrative challenge to a granted patent within 6 months of grant at INPI. INPI reviews and may cancel patents found invalid.
• Judicial nullity action: Available at any time during the patent's life, filed in the federal courts.

Brazil-Specific Strategic Considerations

Use PPH aggressively. Brazil's PPH agreements with the EPO, JPO, and KIPO mean that any allowance at these offices can be leveraged for accelerated Brazilian examination. Given the standard 7–9 year backlog, a PPH request that achieves first examination within 2–3 years represents a major acceleration. Build your global prosecution strategy with Brazilian PPH in mind from the outset.

Consider filing in two stages: broad claims first, narrow claims later. INPI allows divisional applications — applications split from a parent to pursue different claim sets. A parent application with broad claims filed first establishes the priority date; a divisional with claims tailored to the market can be pursued once the commercial landscape is clearer.

Target the Green Technology priority track for clean energy and sustainability inventions. The PT-Verde programme provides meaningfully faster examination for qualifying inventions. If your technology has any connection to renewable energy, water treatment, or emissions reduction, ensure the application is framed to qualify.

Plan for pharmaceutical opposition from the beginning. If you are filing pharmaceutical patents in Brazil, prepare your clinical data package and your response to third-party observations before filing. Engage a Brazilian IP agent with specific pharmaceutical prosecution experience — this is a specialist field within Brazilian IP law.

Cost Summary

Sources

1. INPI Brazil (Instituto Nacional da Propriedade Industrial) — Official national IP authority; filing procedures, fee schedules, and green technology priority track
2. Brazil IP Law 9,279/1996 — Statutory framework for patents including the minimum term guarantee
3. WIPO — Brazil Country Profile — Treaty memberships and IP office information
4. WIPO PCT — National Phase Entry: Brazil — PCT national phase requirements and deadlines

Information current as of April 2026. Patent fees, timelines, and office procedures change — verify with the national patent office before filing.